Clinical Trial Update: A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial evaluating an autologous dendritic cell vaccine expressing the MUC1 antigen in prostate cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Autologous dendritic cell vaccine expressing MUC1 (dendritic cell vaccine expressing MUC1)

Snippet

Sponsor: Hamilton Health Sciences Corporation | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED